Antibody neutralization of coronaviruses

点击翻译按钮获取中文摘要

SARS-CoV-2 is a positive-sense single-stranded RNA virus first isolated in December of 2019. SARS-CoV-2 infection results in a clinical syndrome, coronavirus-induced disease-19 (COVID-19), which is characterized by fever, cough, and shortness of breath that can progress rapidly to respiratory and cardiac failure requiring mechanical ventilation. Virtually all countries and territories have since been affected. Rapid implementation and deployment of an effective SARS-CoV-2 vaccine has the potential to lessen the deleterious effects of infection, especially in vulnerable populations, curb transmission, and end the pandemic. Antibodies are hypothesized to contribute to protection from SARS-CoV-2 infection and COVID-19. The specificities and mechanisms of a protective antibody response have not been established and will be explored in this project.